Request an invite
Atlas/Bispecific antibodies

Bispecific antibodies

T-cell engagers and other dual-targeting antibodies. 18 approved products. Click any cell to read the regulator's sentence.

Check my plan against these

Longest pivotal study, every precedent

Hover a dot · click to open · striped = derived from dosing schedule
041326 wk
ConductedConductedPartial / alternativePartial / payload / alternativeNot conductedNot conductedNot statedNot stated
18 of 18 shown
Open
Bizengrizenocutuzumab · HER2 x HER3 →
Blincytoblinatumomab · CD19 x CD3 →
Columviglofitamab · CD20 x CD3 →
Elrexfioelranatamab · BCMA x CD3 →
Epkinlyepcoritamab · CD20 x CD3 →
Hemlibraemicizumab · FIXa x FX →
Imdelltratarlatamab · DLL3 x CD3 →
Kimmtraktebentafusp · CD3 x gp100 (TCR fusion) →
Korjunycatumaxomab · EpCAM x CD3 →
Lunsumiomosunetuzumab · CD20 x CD3 →
Lynozyficlinvoseltamab · BCMA x CD3 →
Ordsponoodronextamab · CD20 x CD3 →
Removabcatumaxomab · EpCAM x CD3 →
Rybrevantamivantamab · EGFR x MET →
Talveytalquetamab · GPRC5D x CD3 →
Tecvayliteclistamab · BCMA x CD3 →
Vabysmofaricimab · VEGF-A x Ang-2 →
Ziiherazanidatamab · HER2 x HER2 (biparatopic) →